Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Head & Neck 1CNS 1Breast 1

Conditions

Unipolar Major Depression 1Radiation Injuries 1Head and Neck Neoplasms 1Glioblastoma 1Depression 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × Vortioxetine × Clear all
NCT07284628 2025-12-16

ReVoGlio

University of Zurich

Phase 2 Not yet recruiting
78 enrolled
CNS

Glioblastoma

NCT04818099 2021-03-26

Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Unknown
208 enrolled
Head & Neck

Depression, Head and Neck Neoplasms, Radiation Injuries

NCT02637466 2016-09-30

Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

University of Miami

Phase 4 Withdrawn
Breast

Unipolar Major Depression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡